|Spark Therapeutics Inc -- USA Stock|| |
USD 62.41 2.96 4.53%
Co-Founder and Head of Regulatory Strategy
Ms. Jennifer Wellman is CoFounder and Head of Regulatory Strategy of Spark Therapeutics Inc. Prior to joining Spark Ms. Wellman was the Director of Regulatory Interactions for Gene Therapy Studies at the Center for Cellular and Molecular Therapeutics at CHOP. Ms. Wellman also previously held a role as Associate Scientist at Avigen Inc
Age: 36 Founder Since 2013
Wellman holds a B.S. in microbiology and immunology from Queen?s University and an M.S. from the University of New Haven.
The company has return on total asset (ROA)
of (29.55) %
which means that it has lost $29.55 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (60.07) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 36.22 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics Inc has Current Ratio of 9.73 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. Spark Therapeutics, Inc. was founded in 2013 and is headquartered in Philadelphia, Pennsylvania. Spark Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ. It employs 315 people.Spark Therapeutics Inc (ONCE) is traded on NASDAQ in USA. It is located in PENNSYLVANIA, U.S.A and employs 315 people. Spark Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.